Developer docs
API playgroundTry for free, no card

Search company profiles

Viking Therapeutics

Full company profile

uuid0000rca

Namestring
Viking Therapeutics
Legal namestring
Viking Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company headquartered in San Diego, California that develops novel therapeutics for metabolic and endocrine disorders. The company's research leverages expertise in metabolism across four mechanistic platforms: dual GLP-1/GIP receptor agonism (VK2735 in subcutaneous and oral formulations), selective thyroid hormone receptor beta (TRβ) agonism (VK2809 for MASH/NASH and VK0214 for X-linked adrenoleukodystrophy), dual amylin and calcitonin receptor agonism (VK3019 for obesity), and selective androgen receptor modulation (VK5211 for hip fracture recovery). Lead asset VK2735 is in Phase 3 development — the VANQUISH-1 trial (~4,650 patients with obesity) and VANQUISH-2 trial (~1,000 patients with type 2 diabetes and obesity) — with data readouts expected in 2027; subcutaneous VK2735 demonstrated up to 14.7% mean weight loss at 13 weeks in the Phase 2 VENTURE trial, while the oral formulation showed up to 12.2% weight loss.

The company operates a traditional clinical-stage biopharma model with no approved products and no current commercial revenue. Capital formation has been executed through public equity markets — a $250 million offering in March 2023 and a $632.5 million offering in March 2024 — providing a $603 million cash position at March 31, 2026 against quarterly R&D spend exceeding $150 million. Viking is building pre-commercial infrastructure ahead of potential VK2735 approval, including a $150 million manufacturing agreement with CordenPharma running through 2028 and the recent appointments of a Chief Commercial Officer (Neil Aubuchon, ex-Eli Lilly and Amgen) and Chief Medical Officer (Hubert C. Chen, ex-Amylin Pharmaceuticals). The company is publicly traded and operates as an independent entity with no parent company or subsidiaries.

Short descriptiontext

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for metabolic and endocrine disorders, with lead asset VK2735 — a dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity — alongside TRβ agonists, a DACRA, and a SARM in its pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolic disorder therapeutics, obesity drug development, GLP-1 receptor agonists, clinical-stage biopharmaceutical, endocrine disorder treatments
Industry1 code
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Metabolic Disorder Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1No Current Revenue
TypeSubscription Recurring
Description

Viking Therapeutics is a clinical-stage biopharmaceutical company with no approved products or commercial revenue. The company is developing multiple therapeutic candidates and has no product sales as of Q1 2026.

seekingalpha.com
2Future Product Sales
TypeOne Time License
Description

Upon regulatory approval, the company plans to commercialize its drug candidates, primarily VK2735 for obesity, through traditional pharmaceutical sales channels targeting healthcare providers and patients.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for metabolic and endocrine disorders. The company's lead product candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations for the treatment of obesity. Additional pipeline candidates address NASH/MASH, X-linked adrenoleukodystrophy, and hip fracture recovery. None of the company's drug candidates are yet approved or generating commercial revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • VK2735 subcutaneous: up to 14.7% mean weight loss after 13 weeks; up to 88% of patients achieved ≥10% weight loss
+3 more records
Product overview1 text field

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for metabolic and endocrine disorders. The company's product portfolio consists of multiple clinical-stage programs: VK2735 (dual GLP-1/GIP receptor agonist) being developed in both subcutaneous and oral formulations for obesity; VK3019 (amylin receptor agonist) for obesity; VK2809 (TRβ agonist) for MASH/NASH; VK0214 (TRβ agonist) for X-ALD; and VK5211 (SARM) for hip fracture recovery. The company has no commercialized products and is focused on advancing its pipeline through clinical development.

Product and service5 records
1VK2735 (Dual GLP-1/GIP Receptor Agonist)
CategoryMetabolic Disorder Therapeutics - Obesity
Description

VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed in both subcutaneous (weekly injection) and oral (daily tablet) formulations for the treatment of obesity and metabolic disorders. The subcutaneous formulation is in Phase 3 VANQUISH trials and the oral formulation Phase 3 is planned for Q3 2026.

2VK3019 (Dual Amylin and Calcitonin Receptor Agonist)
CategoryMetabolic Disorder Therapeutics - Obesity
Description

VK3019 is a novel dual amylin and calcitonin receptor agonist (DACRA) being developed as a potential treatment for obesity and weight loss. The randomized, double-blind, placebo-controlled single ascending dose Phase 1 trial is being conducted in healthy adults with BMI ≥30.

3VK2809 (Selective TRβ Agonist)
CategoryMetabolic Disorder Therapeutics - Liver Disease
Description

VK2809 is an orally available, small molecule selective thyroid hormone receptor beta (TRβ) agonist with selectivity for liver tissue and the beta receptor subtype, being developed for the treatment of MASH/NASH and associated fibrosis. The Phase 2b VOYAGE trial demonstrated median 38-55% relative change in liver fat and 63-75% NASH resolution rate.

4VK0214 (Selective TRβ Agonist)
CategoryMetabolic Disorder Therapeutics - Rare Disease
Description

VK0214 is an orally available, small molecule selective thyroid hormone receptor beta agonist being developed for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare and often fatal metabolic disorder caused by mutations in the ABCD1 gene. The drug has received FDA orphan drug designation.

5VK5211 (Selective Androgen Receptor Modulator)
CategoryEndocrine Disorder Therapeutics
Description

VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) in development for the treatment of patients recovering from non-elective hip fracture surgery. Phase 2 proof-of-concept trial demonstrated statistically significant increases in lean body mass.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral small-molecule GLP-1 agonists (GSBR-1290) for obesity. Direct comparable to Viking's oral VK2735 formulation.

TypeBroad incumbent
Description

Eli Lilly markets Mounjaro/Zepbound (tirzepatide), the leading dual GLP-1/GIP agonist for obesity and Type 2 diabetes, making it the dominant incumbent Viking must compete against in metabolic disease.

TypeBroad incumbent
Description

Novo Nordisk markets Ozempic/Wegovy (semaglutide), the established GLP-1 obesity franchise, and is developing next-generation candidates including amycretin. Direct competitor to VK2735 in obesity.

TypeDirect peer
Description

Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and MASH. Directly comparable mechanism and indication overlap with VK2735 and VK2809.

TypeEmerging player
Description

Recently public clinical-stage obesity biotech developing injectable and oral amylin and GLP-1-based therapies. Closely comparable to Viking's dual-formulation VK2735 and amylin program VK3019.

TypeDirect peer
Description

Madrigal markets Rezdiffra (resmetirom), the first FDA-approved THR-β selective agonist for MASH. Direct competitor to Viking's VK2809 in MASH/NASH.

TypeDirect peer
Description

Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH with Phase 3 HARMONY data. Direct competitor to Viking's VK2809 in MASH.

TypeDirect peer
Description

Clinical-stage Danish biotech developing petrelintide (amylin analog) and other peptides for obesity. Directly comparable to Viking's DACRA program VK3019 and broader peptide obesity pipeline.

TypeEmerging player
Description

Clinical-stage biotech developing TERN-601 (oral GLP-1) and TERN-501 (THR-β agonist) for obesity and MASH. Comparable to Viking's oral VK2735 and VK2809 programs.

TypeEmerging player
Description

Clinical-stage RNAi-based therapeutics company with metabolic programs including plozasiran and zodasiran for dyslipidemias and rare metabolic diseases. Adjacent peer in metabolic disease R&D.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Viking Therapeutics

Metabolic Disorder Therapeuticsvikingtherapeutics.com

Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for metabolic and endocrine disorders, with lead asset VK2735 — a dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity — alongside TRβ agonists, a DACRA, and a SARM in its pipeline.

What Viking Therapeutics does

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company headquartered in San Diego, California that develops novel therapeutics for metabolic and endocrine disorders. The company's research leverages expertise in metabolism across four mechanistic platforms: dual GLP-1/GIP receptor agonism (VK2735 in subcutaneous and oral formulations), selective thyroid hormone receptor beta (TRβ) agonism (VK2809 for MASH/NASH and VK0214 for X-linked adrenoleukodystrophy), dual amylin and calcitonin receptor agonism (VK3019 for obesity), and selective androgen receptor modulation (VK5211 for hip fracture recovery). Lead asset VK2735 is in Phase 3 development — the VANQUISH-1 trial (~4,650 patients with obesity) and VANQUISH-2 trial (~1,000 patients with type 2 diabetes and obesity) — with data readouts expected in 2027; subcutaneous VK2735 demonstrated up to 14.7% mean weight loss at 13 weeks in the Phase 2 VENTURE trial, while the oral formulation showed up to 12.2% weight loss.

The company operates a traditional clinical-stage biopharma model with no approved products and no current commercial revenue. Capital formation has been executed through public equity markets — a $250 million offering in March 2023 and a $632.5 million offering in March 2024 — providing a $603 million cash position at March 31, 2026 against quarterly R&D spend exceeding $150 million. Viking is building pre-commercial infrastructure ahead of potential VK2735 approval, including a $150 million manufacturing agreement with CordenPharma running through 2028 and the recent appointments of a Chief Commercial Officer (Neil Aubuchon, ex-Eli Lilly and Amgen) and Chief Medical Officer (Hubert C. Chen, ex-Amylin Pharmaceuticals). The company is publicly traded and operates as an independent entity with no parent company or subsidiaries.

Viking Therapeutics firmographics

Firmographics
Name
Viking Therapeutics
Legal name
Viking Therapeutics, Inc.
Website
https://vikingtherapeutics.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for metabolic and endocrine disorders, with lead asset VK2735 — a dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity — alongside TRβ agonists, a DACRA, and a SARM in its pipeline.
Ownership category
akta.pro rank

Viking Therapeutics industry classification

Industry
Product category
Metabolic Disorder Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Metabolic disorder therapeutics
  • Obesity drug development
  • GLP-1 receptor agonists
  • Clinical-stage biopharmaceutical
  • Endocrine disorder treatments

Where Viking Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Viking Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. No Current Revenue: Viking Therapeutics is a clinical-stage biopharmaceutical company with no approved products or commercial revenue. The company is developing multiple therapeutic candidates and has no product sales as of Q1 2026.
  2. Future Product Sales: Upon regulatory approval, the company plans to commercialize its drug candidates, primarily VK2735 for obesity, through traditional pharmaceutical sales channels targeting healthcare providers and patients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Viking Therapeutics product offering

Product offering

Core offering

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for metabolic and endocrine disorders. The company's lead product candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations for the treatment of obesity. Additional pipeline candidates address NASH/MASH, X-linked adrenoleukodystrophy, and hip fracture recovery. None of the company's drug candidates are yet approved or generating commercial revenue.

Product overview

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for metabolic and endocrine disorders. The company's product portfolio consists of multiple clinical-stage programs: VK2735 (dual GLP-1/GIP receptor agonist) being developed in both subcutaneous and oral formulations for obesity; VK3019 (amylin receptor agonist) for obesity; VK2809 (TRβ agonist) for MASH/NASH; VK0214 (TRβ agonist) for X-ALD; and VK5211 (SARM) for hip fracture recovery. The company has no commercialized products and is focused on advancing its pipeline through clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • VK2735 (Dual GLP-1/GIP Receptor Agonist) VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed in both subcutaneous (weekly injection) and oral (daily tablet) formulations for the treatment of obesity and metabolic disorders. The subcutaneous formulation is in Phase 3 VANQUISH trials and the oral formulation Phase 3 is planned for Q3 2026.
  • VK3019 (Dual Amylin and Calcitonin Receptor Agonist) VK3019 is a novel dual amylin and calcitonin receptor agonist (DACRA) being developed as a potential treatment for obesity and weight loss. The randomized, double-blind, placebo-controlled single ascending dose Phase 1 trial is being conducted in healthy adults with BMI ≥30.
  • VK2809 (Selective TRβ Agonist) VK2809 is an orally available, small molecule selective thyroid hormone receptor beta (TRβ) agonist with selectivity for liver tissue and the beta receptor subtype, being developed for the treatment of MASH/NASH and associated fibrosis. The Phase 2b VOYAGE trial demonstrated median 38-55% relative change in liver fat and 63-75% NASH resolution rate.
  • VK0214 (Selective TRβ Agonist) VK0214 is an orally available, small molecule selective thyroid hormone receptor beta agonist being developed for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare and often fatal metabolic disorder caused by mutations in the ABCD1 gene. The drug has received FDA orphan drug designation.
  • VK5211 (Selective Androgen Receptor Modulator) VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) in development for the treatment of patients recovering from non-elective hip fracture surgery. Phase 2 proof-of-concept trial demonstrated statistically significant increases in lean body mass.

Quantifiable outcome

  • VK2735 subcutaneous: up to 14.7% mean weight loss after 13 weeks; up to 88% of patients achieved ≥10% weight loss
  • +3 more outcomes

Companies that use Viking Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Viking Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Viking Therapeutics partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Viking Therapeutics competitors and assessment

Company assessment

Direct peers

  • Structure Therapeutics: Clinical-stage biotech developing oral small-molecule GLP-1 agonists (GSBR-1290) for obesity. Direct comparable to Viking's oral VK2735 formulation.
  • Altimmune: Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and MASH. Directly comparable mechanism and indication overlap with VK2735 and VK2809.
  • Madrigal Pharmaceuticals: Madrigal markets Rezdiffra (resmetirom), the first FDA-approved THR-β selective agonist for MASH. Direct competitor to Viking's VK2809 in MASH/NASH.
  • Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH with Phase 3 HARMONY data. Direct competitor to Viking's VK2809 in MASH.
  • Zealand Pharma: Clinical-stage Danish biotech developing petrelintide (amylin analog) and other peptides for obesity. Directly comparable to Viking's DACRA program VK3019 and broader peptide obesity pipeline.

Broad incumbents

  • Eli Lilly: Eli Lilly markets Mounjaro/Zepbound (tirzepatide), the leading dual GLP-1/GIP agonist for obesity and Type 2 diabetes, making it the dominant incumbent Viking must compete against in metabolic disease.
  • Novo Nordisk: Novo Nordisk markets Ozempic/Wegovy (semaglutide), the established GLP-1 obesity franchise, and is developing next-generation candidates including amycretin. Direct competitor to VK2735 in obesity.

Emerging players

  • Metsera: Recently public clinical-stage obesity biotech developing injectable and oral amylin and GLP-1-based therapies. Closely comparable to Viking's dual-formulation VK2735 and amylin program VK3019.
  • Terns Pharmaceuticals: Clinical-stage biotech developing TERN-601 (oral GLP-1) and TERN-501 (THR-β agonist) for obesity and MASH. Comparable to Viking's oral VK2735 and VK2809 programs.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi-based therapeutics company with metabolic programs including plozasiran and zodasiran for dyslipidemias and rare metabolic diseases. Adjacent peer in metabolic disease R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Viking Therapeutics social profiles

Digital presence

Viking Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Viking Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Viking Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Viking Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viking Therapeutics

What does Viking Therapeutics do?

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for metabolic and endocrine disorders. The company's lead product candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations for the treatment of obesity. Additional pipeline candidates address NASH/MASH, X-linked adrenoleukodystrophy, and hip fracture recovery. None of the company's drug candidates are yet approved or generating commercial revenue.

Is Viking Therapeutics a public or private company?

Viking Therapeutics is a public company. It is classified as public and is currently operating.

When was Viking Therapeutics founded?

Viking Therapeutics was founded in 2012. It employs 51 to 100 people.

Where is Viking Therapeutics based?

Viking Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Viking Therapeutics make money?

Two revenue lines are on record. No Current Revenue is the primary driver. The others are future Product Sales.

Who are Viking Therapeutics's main competitors?

Direct peers on record are Structure Therapeutics, Altimmune, Madrigal Pharmaceuticals, Akero Therapeutics and Zealand Pharma. Broad incumbents are Eli Lilly and Novo Nordisk. Emerging players are Metsera, Terns Pharmaceuticals and Arrowhead Pharmaceuticals.

Does Viking Therapeutics have an API?

No public API is recorded for Viking Therapeutics.

What industry is Viking Therapeutics in?

Viking Therapeutics's product category is Metabolic Disorder Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaViking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptViking Therapeutics CEO Brian Lian discussed the company's ObesityWeek event, highlighting maintenance study data from September. He noted encouraging effects when transitioning patients from weekly to every-other-week dosing, and mentioned ongoing design for Part 2 and future label updates.Quiver QuantitativeNew Analyst Forecast: $VIK Given $111 Price Target | VIK Stock NewsBarclays analyst Brandt Montour set a $111 price target for VIK on 11/18/2026. Insiders have made 29 sales and no purchases in the past six months, while 347 institutional investors added shares and 364 reduced positions in Q3 2026.The Motley FoolHave $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.Viking Therapeutics has four phase 3 trials for VK2735, a GLP-1/GIP agonist, in obesity and obesity with type 2 diabetes. The company raised $547.8 million in a stock offering, and phase 2 data suggest faster weight loss than tirzepatide. Oral trial results are expected in 2028.The Motley FoolHave $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.Viking Therapeutics has four phase 3 trials for VK2735, a GLP-1/GIP agonist, including two 78-week subcutaneous and two 68-week oral trials. The company raised $547.8 million in a stock offering, and phase 2 data showed 21.7% weight loss after 33 weeks. Oral trial results are expected in 2028.Simply Wall StHow New Obesity Trial Data At Viking Therapeutics (VKTX) Has Changed Its Investment StoryViking Therapeutics reported Phase 2 VENTURE data at ObesityWeek 2026 showing VK2735 recipients had meaningful BMI category improvements and broad cardiometabolic marker changes versus placebo after 13 weeks of weekly subcutaneous dosing. The data highlights multi-risk factor obesity benefits, with the next focus on VANQUISH 3 trial outcomes. Analysts project US$118.5 million revenue and US$12.9 million earnings by 2029.YahooViking: 3 Key Takeaways for Long-Term InvestorsViking announced on its Q3 2026 earnings call that it initiated phase 3 registration trials for its oral weight-loss tablet VK2735. The company also reported maintenance studies showing weight loss retention with less frequent dosing and closed offerings generating $575 million, expanding cash to $960 million.The Motley FoolViking: 3 Key Takeaways for Long-Term InvestorsViking Therapeutics initiated phase 3 registration trials for its oral weight-loss tablet VK2735 on Oct. 28, 2026. The company raised $575 million in capital, expanding cash to $960 million. Management highlighted dosing flexibility and commercial preparation.YahooShould You Trim Or Add To Your Viking Therapeutics Position?Viking Therapeutics' stock is valued at $3.45 billion, betting on its obesity drug VK2735, which has not yet produced Phase 3 results. The company has $705 million in cash after debt, enough for about 15 months at the September quarter's pace, while its operating loss rose to $649 million. Phase 3 trials continue, but the drug's success remains the key question.BenzingaViking Therapeutics Stock Dips Despite Positive VK2735 Data: What’s Going On? - Viking Therapeutics (NASDViking Therapeutics shares fell about 5% on Monday after the company presented Phase 2 VENTURE trial data at ObesityWeek. The data showed 74% of participants improved by at least one BMI category after 13 weeks, versus 15% on placebo. The stock remains below its 200-day moving average, with the Phase 3 VANQUISH program as the next test.Simply Wall StViking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws FocusViking Therapeutics presented new VK2735 obesity data at ObesityWeek, with Phase 2 VENTURE analysis linking weekly injections to BMI shifts and cardiometabolic changes. The stock rose 16.09% in one month to $29.22, while a bullish analyst fair value of $125 suggests 77% undervaluation, though a DCF model flags overvaluation at $3.16.